Basis of presentation and statement of compliance (Details) € in Millions, $ in Millions |
Aug. 18, 2026
EUR (€)
|
Aug. 10, 2026
USD ($)
|
|---|---|---|
| Strategic partnership with Swedish Orphan Biovitrum AB | ||
| Disclosure of non-adjusting events after reporting period [line items] | ||
| Upfront payment, commitment | $ | $ 75 | |
| Capital increase | Share capital | ||
| Disclosure of non-adjusting events after reporting period [line items] | ||
| Proceeds from issue of ordinary shares | € | € 30 |